Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemoglobin regulatory region encompasses DNA sequences, including locus control regions (LCRs), promoters, enhancers, and silencers, that control the expression of hemoglobin genes within the β-globin gene cluster. These elements regulate developmental switching between fetal and adult forms of hemoglobin and are crucial for proper erythropoiesis. Mutations or polymorphisms within these regions can disrupt hemoglobin expression and lead to diseases like sickle cell disease and β-thalassemia. Therapeutic strategies are being developed to target trans-factors interacting with these regulatory elements to reactivate fetal hemoglobin production.
Therapeutic strategies focus on modulating the activity of transcription factors (e.g., BCL11A) that interact with the regulatory region to reactivate fetal hemoglobin production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin Regulatory Region.